ALEXANDER, RICHARD,艾力德,CONNORS, RICHARD W,可诺斯,可諾斯,CUMMINGS, MAXWELL D.,古明斯,GALEMMO, ROBERT A.,卡勒莫,HUFNAGEL, HEATHER RAE,古那尔,古那爾,JOHNSON, DANA L.,强森那,強森那,KHALIL, EHAB,何利尔,何利爾,LEONARD, KRIST
申请号：
TW095147762
公开号：
TWI399378B
申请日:
2006.12.20
申请国别(地区):
TW
年份:
2013
代理人:
摘要：
The invention is directed to triazolopyridazine compounds of FormulaI:where R1, R5, R6, R7, R8, and A are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of c-Met, and the use of such compounds to reduce or inhibit kinase activity of c-Met in a cell or a subject, and modulate c-Met expression in a cell or subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to c-Met. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.本發明有關式I之三唑并嗒類化合物：其中R1、R5、R6、R7、R8及A係如本發明所定義，有關該等化合物作為蛋白質酪胺酸激酶調節劑(尤其是c－Met之抑制劑)的用途及該等化合物降低或抑制c－Met於細胞或個體中之激酶活性且於細胞或個體中調節c－Met表現的用途及該等化合物用以預防或治療個體與c－Met有關之細胞增殖性病症及/或病症等。本發明另外有關包含本發明化合物之醫藥組成物且有關治療諸如癌症及其他細胞增殖性病症之病況的方法。
